Cargando…
Human Antibody Therapeutics For Viral Disease
The articles in this volume have been selected to demonstrate the progress in the development of human antibody therapeutics for viral disease. Keck et al. review the nature of the immune response to the Hepatitis C virus (HCV) and the details of viral neutralization by antibodies, providing a conce...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Berlin, Heidelberg :
Springer Berlin Heidelberg : Imprint: Springer,
2008.
|
| Edición: | 1st ed. 2008. |
| Colección: | Current Topics in Microbiology and Immunology,
317 |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-540-72146-8 | ||
| 003 | DE-He213 | ||
| 005 | 20220111134831.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2008 gw | s |||| 0|eng d | ||
| 020 | |a 9783540721468 |9 978-3-540-72146-8 | ||
| 024 | 7 | |a 10.1007/978-3-540-72146-8 |2 doi | |
| 050 | 4 | |a QR355-502 | |
| 072 | 7 | |a PSGL |2 bicssc | |
| 072 | 7 | |a MED052000 |2 bisacsh | |
| 072 | 7 | |a PSG |2 thema | |
| 082 | 0 | 4 | |a 579.2 |2 23 |
| 082 | 0 | 4 | |a 616.96 |2 23 |
| 245 | 1 | 0 | |a Human Antibody Therapeutics For Viral Disease |h [electronic resource] / |c edited by Scott K. Dessain. |
| 250 | |a 1st ed. 2008. | ||
| 264 | 1 | |a Berlin, Heidelberg : |b Springer Berlin Heidelberg : |b Imprint: Springer, |c 2008. | |
| 300 | |a XII, 190 p. 18 illus., 7 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Current Topics in Microbiology and Immunology, |x 2196-9965 ; |v 317 | |
| 505 | 0 | |a Therapeutic Control of Hepatitis C Virus: The Role of Neutralizing Monoclonal Antibodies -- Antibodies for HIV Treatment and Prevention: Window of Opportunity? -- Human Monoclonal Antibody and Vaccine Approaches to Prevent Human Rabies -- Immunoprophylaxis of RSV Infection: Advancing from RSV-IGIV to Palivizumab and Motavizumab -- The Molecular Basis of Antibody Protection Against West Nile Virus -- Exploring the Native Human Antibody Repertoire to Create Antiviral Therapeutics. | |
| 520 | |a The articles in this volume have been selected to demonstrate the progress in the development of human antibody therapeutics for viral disease. Keck et al. review the nature of the immune response to the Hepatitis C virus (HCV) and the details of viral neutralization by antibodies, providing a conceptual model for the clinical use of HCV-specific antibodies. Huber et al. summarize the initial clinical experiences with antibody therapeutics for Human Immunodeficiency Virus that can be targeted to either the HIV virion or to host cell proteins. A discussion of the breadth immune strategies that is required to control human rabies is provided by Nagarajan et al., with a particular focus on India and other countries in which rabies is endemic. The development of pavilizumab for RSV prophylaxis is reviewed in Wu et al., in addition to results of antibody optimization studies that provide surprising insights and have broad general implications for anti-viral antibody engineering. Melhop and Diamond explicate the biology of West Nile Virus as a general model for flaviviruses, while using their cloned antibodies as a springboard to consider the mechanisms of WNV neutralization. The volume concludes with a description of methods to clone human antibodies in their native configurations, which access a class of antibodies that differ from those obtained by recombinant DNA or transgenic mouse methods. The articles in this volume are definitive and comprehensive reviews written by experts who have sought to define the principles of viral neutralization by human antibodies. They explore and anticipate the obstacles and opportunities that will be encountered as the power of human antibodies is harnessed to address the vast, un-met need for effective anti-viral therapeutics. | ||
| 650 | 0 | |a Virology. | |
| 650 | 1 | 4 | |a Virology. |
| 700 | 1 | |a Dessain, Scott K. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783642091315 |
| 776 | 0 | 8 | |i Printed edition: |z 9783540837701 |
| 776 | 0 | 8 | |i Printed edition: |z 9783540721444 |
| 830 | 0 | |a Current Topics in Microbiology and Immunology, |x 2196-9965 ; |v 317 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-540-72146-8 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||